Overview

Overview

Gmax Biopharm LLC. is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody development, to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer. Founded in 2010, Gmax has attracted a talent pool of young scholars and US returnees. The core leadership for R&D has averaging 20 years of extensive biopharmaceutical industry experiences in multinational companies like Amgen, BMS and Genentech. Leveraging its proprietary world class GPCR antibody and Bibody platforms, Gmax has established a robust pipeline for diabetes, obesity, NASH, PAH and heart failure: two antibodies in clinical trials, 7 antibodies/Bibodies in preclinical testing, and 9 antibodies/Bibodies in various stages of early discovery.